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morbidities than either CCI or ACE-27. The HCT-CI should be
used prospectively to stratify pts in future clinical trials (Table 1).
Table 1. Multivariable Cox Regression Models
Risk factor
FHCRC Pts (n  137) MDACC Pts (n  70)
HR (95% CI)
for Higher
NRM
HR (95% CI)
for Worse
Survival
HR (95% CI)
for Higher
NRM
HR (95% CI)
for Worse
Survival
HCT-CI
scores
0 1.0 1.0 1.0 1.0
1–2 0.95
(0.2–4.4)
2.32
(0.9–6.0)
2.41
(0.2–27)
2.34
(0.7–8.0)
>3 6.35
(1.7–24)
8.88
(3.5–22)
5.72
(0.7–44)
2.95
(1.0–8.9)
Donor Related 1.0 1.0 1.0 1.0
Unrelated 1.94
(0.6–6.7)
3.05
(1.4–6.5)
0.44
(0.1–3.6)
1.45
(0.6–3.8)
Stem cell
source
G-PBMC 1.0 1.0 1.0 1.0
Marrow 5.49
(1.5–21)
3.31
(1.5–7.4)
1.48
(0.5–4.8)
0.94
(0.4–2.1)
Conditioning Myeloablative 1.0 1.0 1.0 1.0
Reduced
intensity
1.04
(0.2–5.7)
0.48
(0.2–1.4)
1.99
(0.5–8.0)
1.29
(0.5–3.4)
Age <50 1.0 1.0 1.0 1.0
>50 1.54
(0.4–6.2)
2.33
(1.0–5.2)
0.62
(0.2–2.5)
0.70
(0.3–1.9)
FHCRC indicates Fred Hutchinson Cancer Research Center;
MDACC, M. D. Anderson Cancer Center; HCT-CI, hemato-
poietic cell transplantation-speciﬁc comorbidity index; and G-
PBMC, G-CSF mobilized peripheral blood mononuclear cells.
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INTENSITY CONDITIONING
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Allogeneic stem-cell transplantation (SCT) is a potentially cura-
tive approach for patients (pts) with hematological malignancies.
However, elderly pts have often been deterred from this approach
due to high risks of treatment-related complications and less
chance of getting suitable donors. Umbilical cord blood transplan-
tation with reduced-intensity conditioning (RI-UCBT) allowed
extension of allogeneic SCT to a wider pt population including the
elderly. However, there are only limited data on the feasibility and
outcome in elderly pts. In this study, we report our experience with
63 pts aged 55 years old and older having RI-UCBT. The median
age was 62 years (range, 55-79). Thirty-six pts were over 60,
including 6 pts over 70. Diagnoses included AML (n  20), ALL
(n  7), MDS (n  8), ATL (n  14), CML (n  4), NHL (n 
7), MM (n  1), and SAA (n  2). The preparative regimen
consisted of ﬂudarabine (125 mg/m2) combined with melphalan
(80 mg/m2) and 4 Gy total body irradiation for most of the patients
(n  60). Either cyclosporine alone (n  37) or tacrolimus alone
(n  26) were employed as GVHD prophylaxis. Forty-eight pts
engrafted with a median of 19 days (range, 11-53). Five pts died
prior to engraftment. With a median follow-up of 116 days (range,
11-1092), 20 pts are alive and 43 have died; 32 of treatment-related
causes (16 of infection, 7 of GVHD, 4 of IP, 2 of TMA, and 3 of
others) and 12 of relapse. The probabilities of overall survival at
2-year after SCT were 32.8% (95 CI, 15-51%). Acute GVHD
occurred in 31 pts, 22 of those were in grade II-IV. Pts aged 62 and
older had an OS of only 16.1%, whereas pts younger than 62 years
old had an OS of 48.5% (P  .008). There was a tendencies for pts
in standard risk group (acute leukemia in remission, CML AP,
SAA, and untreated MDS) to have better OS of 54.5% than those
in high risk group (all the rest, OS  28.3%, P  .06), and for pts
who had tacrolimus as GVHD prophylaxis (OS  46.2%) than
those with cyclosporine (OS  23.7%, P  .09), although the
differences were not statistically signiﬁcant. When the pts aged 62
and older were analysed, tacrolimus group (n  11) tended to have
a greater chance to survive (OS36.4%) than cyclosporine group
(n 11, OS5.0%). In conclusion, RI-UCBT is feasible in elderly
pts. Even within this group of pts, older age (62 years and older) is
still an unfavorable factor for survival. Tacrolimus as GVHD
prophylaxis may, however, have a potential to improve outcome for
those in higher age range.
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Patients with systemic lupus erythematosus (SLE) usually re-
spond well to immunosuppressive medications. However, there
is a subset of refractory SLE patients for whom current strate-
gies are insufﬁcient to control disease. Here we report results of
autologous non-myeloablative hematopoietic stem cell trans-
plantation (HSCT) single arm trial performed at Northwestern
University Feinberg School of Medicine between February 1997
and January 2005 which involved 50 patients with SLE refrac-
tory to standard immune suppressive therapies and either organ-
or life-threatening visceral involvement. The primary endpoint
was survival, both overall survival and disease free survival.
Secondary endpoints include systemic lupus erythematosus dis-
ease activity index (SLEDAI), serology (ANA and anti-ds
DNA), complement (C3 and C4), and changes in renal and
pulmonary organ function assessed pre-treatment and at 6, 12
months and then yearly for 5 years. Peripheral blood stem cells
were mobilized with intravenous (IV) cyclophosphamide (CY)
(2.0 g/m2) and subcutaneous G-CSF (5 g/kg/day). The graft
was enriched ex vivo by CD34 immunoselection. Conditioning
regimen consisted of IV CY (200 mg/kg) and equine anti-
thymocyte globulin (90 mg/kg). Fifty patients were enrolled and
underwent stem cell mobilization. Two patients died after mo-
bilization, one from disseminated mucormycosis and another
from active lupus after postponing the transplant for 4 months.
Forty-eight patients underwent lupus non-myeloablative HSCT
with no treatment related mortality. By intention to treat, treat-
ment related mortality was 2% (1/50). With a mean follow-up of
29 months (range 6 month to 7.5 years), overall survival was
84%, and probability of disease free survival at 5 years post
transplant was 50%. SLEDAI, ANA, anti-ds DNA, comple-
ment, and lung diffusion capacity of carbon monoxide adjusted
for hemoglobin (DLCOadj) signiﬁcantly statistically (P  .05)
improved. Renal function assessed by creatinine and creatinine
clearance remained stable overall. Results of our trial suggest
that in patients with treatment refractory SLE autologous non-
myeloablative HSCT markedly ameliorates disease activity and
so confers long term disease remission, improvement in sero-
logic markers, and either stabilization or reversal of organ dys-
function.
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